Last reviewed · How we verify

Phenylephrine bolus 50 micrograms — Competitive Intelligence Brief

Phenylephrine bolus 50 micrograms (Phenylephrine bolus 50 micrograms) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic agonist. Area: Cardiovascular.

marketed Alpha-1 adrenergic agonist Alpha-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Phenylephrine bolus 50 micrograms (Phenylephrine bolus 50 micrograms) — Rawalpindi Medical College. Phenylephrine is an alpha-1 adrenergic agonist that causes vasoconstriction and increases blood pressure by stimulating alpha-1 receptors on vascular smooth muscle.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Phenylephrine bolus 50 micrograms TARGET Phenylephrine bolus 50 micrograms Rawalpindi Medical College marketed Alpha-1 adrenergic agonist Alpha-1 adrenergic receptor
Bupivacaine-adrenaline Bupivacaine-adrenaline University of Aarhus marketed Local anesthetic with vasopressor Voltage-gated sodium channels; alpha-1 adrenergic receptors (adrenaline component)
RASi plus carvedilol RASi plus carvedilol Federal University of Minas Gerais marketed ACE inhibitor or ARB combined with non-selective beta-blocker Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor
Cyclopentolate+tropicamide+phenylephrine Cyclopentolate+tropicamide+phenylephrine Pontificia Universidad Catolica de Chile marketed Anticholinergic + sympathomimetic combination Muscarinic acetylcholine receptors (M1-M5); alpha-1 adrenergic receptor
Norepinephrine intravenous infusion Norepinephrine intravenous infusion University of Sao Paulo marketed Catecholamine; sympathomimetic amine Alpha-1 adrenergic receptor; beta-1 adrenergic receptor
labetalol intravenous labetalol intravenous Haseki Training and Research Hospital marketed Alpha-beta adrenergic antagonist Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Midodrine + pyridostigmine Midodrine + pyridostigmine Seoul National University Hospital marketed Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination Alpha-1 adrenergic receptor; acetylcholinesterase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic agonist class)

  1. Allergan · 2 drugs in this class
  2. EMS · 1 drug in this class
  3. Institute of Liver and Biliary Sciences, India · 1 drug in this class
  4. Medical University of Graz · 1 drug in this class
  5. Rawalpindi Medical College · 1 drug in this class
  6. Tehran Heart Center · 1 drug in this class
  7. Actavis Inc. · 1 drug in this class
  8. University Tunis El Manar · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Phenylephrine bolus 50 micrograms — Competitive Intelligence Brief. https://druglandscape.com/ci/phenylephrine-bolus-50-micrograms. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: